granisetron- granisetron injection
sandoz inc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. pregnancy category b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. benzyl alcohol may cross the placenta. granisetron hydrochlori
granisetron hydrochloride injection sdz solution
sandoz canada incorporated - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists
granisetron hydrochloride injection liquid
sandoz canada incorporated - granisetron (granisetron hydrochloride) - liquid - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists
granisetron fresenius injection 1mgml
fresenius kabi (singapore) pte ltd - granisetron hydrochloride 1.12mg eqv to granisetron - injection, solution - granisetron hydrochloride 1.12mg eqv to granisetron 1mg/ml
granisetron hydrochloride tablet, film coated
orchidpharma inc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.
granisetron hydrochloride tablet, film coated
northstar rx llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.
granisetron hydrochloride tablet
ascend laboratories, llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride 1 mg - granisetron hcl is indicated for the prevention of : - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hcl is contraindicated in patients with known hypersensitivity to the drug or any of its components.
granisetron hydrochloride injection
wockhardt limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. chemotherapy-induced nausea and vomiting [see dosage and administration (2)] for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established.
granisetron-aft, granisetron (as hydrochloride) 3 mg/3 ml, concentrated injection, clear type i glass ampoule
aft pharmaceuticals pty ltd - granisetron hydrochloride -
granisetron-aft, granisetron (as hydrochloride) 1 mg/ml, concentrated injection, clear type i glass ampoule
aft pharmaceuticals pty ltd - granisetron hydrochloride -